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Abstract While the beneficial effects of secondary
prevention of cardiovascular disease are undisputed,
implementation remains challenging. A gap between
guideline-mandated risk factor targets and clinical re-
ality was documented as early as the 1990s. To ad-
dress this issue, research groups in the Netherlands
have performed several major projects. These projects
address innovative, multidisciplinary strategies to im-
prove medication adherence and to stimulate healthy
lifestyles, both in the setting of cardiac rehabilitation
and at dedicated outpatient clinics. The findings of
these projects have led to changes in prevention and
rehabilitation guidelines.
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Introduction
While the beneficial effects of secondary prevention
of cardiovascular disease (CVD) are undisputed, im-
plementation remains challenging. A gap between
guideline-mandated risk factor targets and clinical re-
ality was documented as early as the 1990s. Both
medical therapy of biometric risk factors and inter-
ventions to modify lifestyle have consistently been
shown to lag behind increasingly stringent guidelines
[1–3]. To address this issue, research groups in the
Netherlands have performed several major projects.
First, using data from landmark trials, various models
have been developed to predict the effect of different
treatments for individual patients in terms of abso-
lute risk, integrated into a web-based tool (www.u-
prevent.com). Second, large randomised trials have
been performed to investigate interventions to im-
prove the quality of secondary prevention. These trials
address innovative, multidisciplinary strategies to im-
prove medication adherence and to stimulate healthy
lifestyles, both in the setting of cardiac rehabilitation
and at dedicated outpatient clinics. The findings of
these projects have led to changes in prevention and
rehabilitation guidelines, and the main findings, im-
plications and opportunities for further research are
outlined in this paper.
U-Prevent prediction models
In an increasingly complex field of treatment modali-
ties and strategies for patients with CVD, decisions on
initiation or intensification of preventive treatment
can be assisted by assessing individual anticipated
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clinical benefit, derived from prediction models. Key
models have been integrated into an easy-to-use
web-based tool (www.u-prevent.com). These models
cover a large variety of patients, including medium-
term risk estimation for patients with established CVD
(SMART) [4], and in individuals aged >70 years with
and without established CVD [5], in addition to life-
time risk estimation and treatment effect in patients
with a broad spectrum of CVD (SMART-REACH) [6],
and diabetes mellitus type 2 (DIAL) [7]. Such predic-
tion models are rapidly becoming important tools for
clinicians aiming to personalise preventive therapy in
patients with CVD.
Experiences from the randomised RESPONSE 1
and 2 trials
While complex interventions have been shown to be
moderately successful in secondary prevention, im-
plementation of such programs outside research set-
tings has been limited (for example the large-scale
EuroAction trial) [8]. The Randomised Evaluation of
Secondary Prevention by Outpatient Nurse SpEcial-
ists (RESPONSE) 1 (2006–2009) trial (n= 754) was de-
signed to quantify the impact of a practical, hospi-
tal-based nurse coordinated prevention program, in-
tegrated into the routine clinical care of patients in
the first year after an acute coronary syndrome (ACS)
[9]. The nurse-coordinated program consisted of up
to four outpatient clinic visits focusing on (1) healthy
lifestyle; (2) biometric risk factors; and (3) medication
adherence, on top of usual care. At 12-months follow-
up, the estimated overall impact on cardiovascular risk
was a 17% relative reduction in patients in the in-
tervention group as compared with patients receiving
only usual care (p= 0.021). This difference was largely
driven by intensified medication titration [10], with
better treatment to target levels for LDL cholesterol
and blood pressure. This was associated with slight
increases in health-related quality of life, and a reduc-
tion in depressive symptoms in patients randomised
to the nurse-coordinated program [11]. There were
only slight improvements in self-reported lifestyle pa-
rameters such as physical activity and diet, and no
improvements in smoking cessation or body mass in-
dex. Surprisingly, a decrease in emergency room pre-
sentations/readmissions was observed, in favour of
individuals attending the nurse-coordinated program
(86 vs 132, p=0.023), potentially reflecting the coun-
selling part of the nurse-coordinated program and the
positive changes in quality of life and confidence, and
reduced depressive symptoms. We therefore recom-
mended that nurse-coordinated programs should be
part of the usual care of patients with an ACS, a recom-
mendation which was adopted by the ESC prevention
guidelines (level of evidence IIa) [1].
Based on the findings from RESPONSE-1, the
RESPONSE-2 trial was designed (2013–2016) [12].
The RESPONSE-2 trial continued with the concept
of the central role of a coordinating nurse special-
ist but focused specifically on lifestyle modification
and partner participation. To increase the probability
of successful lifestyle modification, the role of the
nurse in RESPONSE-2 was to identify risk profiles,
to motivate patients and to refer both patients and
their partners to readily available community-based
commercial lifestyle interventions (weight reduction,
smoking cessation and physical activity programs).
A total of 824 patients with ACS or coronary revas-
cularisation were randomised to either usual care,
this time including RESPONSE-1 nurse visits, or to
the intervention group, which consisted of usual care
and RESPONSE-1 visits, plus coordinated referrals
to external lifestyle programs for patients and their
partners, if applicable. Due to the complex inter-
play of risk factors and risk factor modification in
secondary prevention, a composite overall outcome
measure was defined to take not only improvement
of lifestyle-related risk factors into account, but also
deterioration. Thus, a strict definition of success-
ful lifestyle modification was used for the primary
outcome: a clinically relevant improvement in ≥1
qualifying lifestyle-related risk factor at 12-months
follow-up (weight, smoking, physical activity) without
deterioration in the other risk factors. At 12-months
follow-up, 37% of patients in the intervention group
versus 26% in the usual care group (p=0.002) reached
the primary outcome, i.e. showed a net improvement
in ≥1 lifestyle-related risk factor. The effect was the
most prominent in weight reduction (≥5% weight
reduction was 27% for the intervention vs. 14% for
usual care, p< 0.001). Active partner participation
in the intervention group was associated with a sig-
nificantly greater success rate (46% in this subgroup
Dutch contribution to the field
 The web-based tool www.u-prevent.com and the
underlying models have been seminal in cardio-
vascular risk prediction and estimation of treat-
ment effects.
 Nurse-coordinated programs (RESPONSE-1 and
RESPONSE-2 randomised trials) improve risk
factor control, medication optimisation, and re-
duce non-cardiac emergency room presentation.
 Nurse-coordinated referral to community-based
lifestyle programs is successful in improving
lifestyle-related risk factors, especially for weight
reduction.
 Adding face-to-face physical activity counselling
as an extension to standard cardiac rehabilita-
tion results in improvements in daily step counts
(OPTICARE randomised trial).
 Cardiac telerehabilitation (FIT@Home random-
ised trial) is non-inferior to conventional cardiac
rehabilitation, and is cost-effective.
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reached the primary outcome), while the absence of
a partner in the usual care group was associated with
the lowest success rate (10%). These findings indicate
that referral of patients with CVD and their partners
to a comprehensive set of community-based lifestyle
programs improves lifestyle-related factors more than
guideline-based usual care alone [12].
Optimising cardiac rehabilitation
Although cardiac rehabilitation has well-known ben-
efits, current programs seem insufficient to improve
physical activity [13, 14]. The OPTICARE (OPTImizing
CArdiac Rehabilitation) research group aims to opti-
mise cardiac rehabilitation with regard to adopting
a healthy lifestyle. In the OPTICARE-1 randomised
controlled trial (RCT), the effects of extending car-
diac rehabilitation with additional behavioural coun-
selling (face-to-face group sessions or individual tele-
phone sessions) were investigated in 914 ACS patients
[15]. Compared with standard cardiac rehabilitation,
adding face-to-face physical activity counselling re-
sulted in additional improvement in daily step counts
[16]. Furthermore, the face-to-face counselling re-
sulted in an improvedmaintenance of physical fitness
up to 12 months and in long-term reductions in fa-
tigue [17]. The extra counselling sessions did not con-
fer additional benefits with respect to blood pressure,
cholesterol, or smoking. Patients largely reached the
target levels for these risk factors following standard
cardiac rehabilitation [15]. Telephone counselling did
not provide additional benefits, emphasising the im-
portance of face-to-face contact.
Selected subgroups, such as patients with obesity
and women, seem less likely to profit from cardiac re-
habilitation [18, 19]. In the OPTICARE XL RCT, the ef-
fectiveness of a novel cardiac rehabilitation program
for obese patients is currently being investigated in
201 patients with coronary artery disease (CAD) or
atrial fibrillation. The program includes small group
participation, self-management, and physical training
programs. Results from a pilot study (n= 17) showed
that in the first 3 months, patients significantly im-
proved their health-related quality of life by 24%, fit-
ness by 15%, and reduced their BMI by 6%. Results of
the full study are expected in 2021.
Specific lessons
In both RESPONSE-1 and RESPONSE-2, the OPTI-
CARE RCT [9, 12, 15], and in European survey data
[20, 21], a highly stable rate of smoking cessation is
observed of ~50% after an ACS or revascularisation.
The majority of successful quitters quit during or im-
mediately after hospitalisation [22], regardless of par-
ticipation in smoking cessation programs. Immedi-
ate quitters even preferred not to attend smoking ces-
sation programs but were highly motivated for other
lifestyle programs [23]. The effect of an acute coro-
nary event should therefore not be underestimated in
motivating patients to stop smoking; however, hard-
core smokers remain an important challenge.
Individual choices of lifestyle programs are not typ-
ically directly related to risk profiles. Individuals with
overweight frequently chose physical activity pro-
grams instead of weight reduction programs, while ex-
smokers frequently chose weight-reduction programs.
Currently, most lifestyle modification programs select
individuals based on the presence of a single specific
risk factor. However, from a patient’s perspective it
is preferable to comprehensively address all relevant
lifestyle-related risk factors and to discuss a patient’s
perspectives and preferences. Studies investigating
personalisation of lifestyle interventions are therefore
urgently needed.
The RESPONSE-1 and RESPONSE-2 trials demon-
strated that risk profiles can be improved at 12 months
after the index event. However, several challenges re-
main. First, the long-term sustainability of these
improvements needs to be evaluated at longer follow-
up. Three-year follow-up data from the RESPONSE-2
trial are currently being analysed. Second, in spite of
these successful outcomes, residual risk at 12 months
is still considerable. With the arrival of new pharma-
cological agents targeting established risk factors (e.g.
antithrombotics, anticoagulation, overweight, LDL
reduction, and novel cholesterol-lowering strategies)
and newly identified risk factors (e.g. inflammation
and triglycerides), the complexity of secondary pre-
vention will significantly increase. The costs of such
strategies are high, and no study has yet investigated
how these agents should be integrated into daily
practice and in which combinations, with or with-
out intensive lifestyle interventions. Therefore, there
is a need for further secondary prevention trials to
investigate how to implement value-based, patient-
centred treatment strategies (Box 1).
E-health: cardiac telerehabilitation
In cardiac telerehabilitation (CTR), components of
cardiac rehabilitation programs are offered outside
the environment of the rehabilitation centre, using
remote communication and devices to monitor pa-
rameters, such as heart rate and physical activity. This
may reduce accessibility barriers (e.g. travelling), but
may also increase patients’ self-management skills,
Box 1 Future research opportunities
 Consolidation of lifestyle modification at longer
follow-up
 Implementation of value-based, patient-centred
treatment strategies, i.e. personalisation
 Improve quality and outcomes of CR
 Further development of telerehabilitation
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resulting in sustainable behavioural change [24, 25].
In recent years, several studies have evaluated the
effects of CTR. The FIT@Home study [26] was one of
the first large RCTs investigating CTR versus centre-
based cardiac rehabilitation [27, 28]. In total, 90 pa-
tients with CAD with low to moderate risk of recurrent
CVD events were randomised to a 12-week program
of either centre-based or home-based exercise train-
ing. The centre-based group participated in group-
based training sessions (2 sessions of 45–60min/
week) based on continuous training at 75–80% maxi-
mal heart rate. The intervention group performed the
same training program at home after three familiari-
sation sessions at the cardiac rehabilitation centre,
using a heart rate monitor and uploading training
data to a web application. Patients received weekly
feedback by telephone from their physical therapist
and were encouraged to continue using the heart rate
monitor and web application after 12 weeks. After
1 year, there were no between-group differences for
the primary outcomes of physical fitness (peakVO2)
and objectively assessed physical activity [29]. Cost-
effectiveness analysis showed that societal costs per
patient were 3160 lower for those in the home-based
group, mainly driven by earlier work resumption. Al-
though highly cost-effective, the FIT@Home inter-
vention did not show superior results with respect
to physical fitness or activity behaviour as compared
with centre-based cardiac rehabilitation. Therefore,
a second RCT was designed, aiming to demonstrate
superior long-term effects of CTR with respect to
exercise behaviour. The SmartCare-CAD study has
randomised 300 patients with CAD to either centre-
based or home-based training [30]. Unique to this
trial is that patients are provided feedback not only
on adherence to prescribed training sessions but also
on daily energy expenditure, and the intervention in-
cludes relapse prevention and tailored patient goals.
Results of the SmartCare-CAD trial are expected to be
published later this year.
Conclusion
Implementation remains a central issue in secondary
prevention of CVD. For drug-related therapy this is
challenging, and for changing lifestyle-related risk fac-
tors even more challenging. Only a minority of pa-
tients are able to successfully and permanently cor-
rect all relevant lifestyle issues. Both patient and care-
giver factors impact the overall success rate and need
to be targeted in ongoing and future investigations.
Major developments are seen in individualising the
estimation of the risk of recurrent events and in de-
signing individual preventive programs, based on pa-
tients’ characteristics and preferences. In the actual
programs, there have been important steps in involv-
ing the patient’s partner, addressing patient prefer-
ences and in the application of home-based or com-
munity-based programs, including remote monitor-
ing and coaching. Given the significant benefits to
patients if the cause of their disease is successfully
treated, we should continue to make every effort to
improve the efficacy of programs for secondary pre-
vention of CAD.
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